MarketMoodz
CONNECT Trial Boosts Dexcom G7 Case for Type 2 CGM Adoption
Dexcom shares jumped roughly 5.5% to about $76.84 after Benzinga reported positive results from the CONNECT randomized trial showing the G7 continuous glucose monitor lowered A1C in adults with Type 2 diabetes who aren’t on insulin. If verified, those results — larger A1C drops, higher time-in-range, and high device use — could strengthen payer coverage and expand a recurring-revenue market beyond Type 1 patients.
Key Takeaways
- DXCM rose about 5.5% on the day to roughly $76.84 following CONNECT coverage.
- CONNECT reported an average A1C reduction of 1.6 percentage points from a baseline of 8.8% for G7 users.
- Time-in-range improved to 62% for G7 users versus 41% for control at 26 weeks, with median daily device use at 97%.
- 82% of G7 users achieved at least a 0.5% A1C reduction; 68% hit <7.5% and 46% hit <7.0% by week 26.
- A six-month extension will assess 12-month durability; payer coverage and reimbursement remain the key risks to adoption.
People Involved
- No specific individuals mentioned
Entities Involved
- DexCom (DXCM)Manufacturer of the G7 continuous glucose monitor and the primary company affected by CONNECT results
- AbbottCompetitor in the continuous glucose monitoring market
- MedtronicCompetitor in the continuous glucose monitoring and diabetes device market
- CONNECT trialRandomized controlled clinical study evaluating Dexcom G7 in adults with Type 2 diabetes not using insulin
- BenzingaNews outlet reporting the CONNECT results and market reaction
MarketMoodz Analysis
For investors, the headline numbers from CONNECT — a 1.6 percentage-point average A1C drop from an 8.8% baseline and a jump in time-in-range to 62% — point to a clear commercial opportunity: expand CGM use into the much larger population of Type 2 patients not on insulin. CGMs drive recurring consumables sales (sensors and transmitters) and higher lifetime value per user than one-off devices. A credible clinical case that CGM use meaningfully improves glycemic control could accelerate payer reimbursement decisions and widen the accessible market, supporting revenue and margin upside if adoption follows.
That upside comes with caveats. The CONNECT numbers reported in secondary coverage show some internal inconsistencies and have not been independently verified against a primary publication or Dexcom press release; investors should treat the data as promising but preliminary. Reimbursement policy has historically lagged for Type 2 non-insulin users. Abbott and Medtronic are established competitors with their own clinical programs and payer relationships, so any market-share gains for Dexcom will depend on pricing, coverage decisions, and real-world adherence beyond a controlled trial. The six-month extension to 12 months is a critical check on durability.
What to watch next: the primary CONNECT publication or a Dexcom press release with full data and statistical details; formal payer guidance or coverage updates from major insurers and Medicare; trends in weekly or quarterly sensor shipments and revenue; and follow-up 12-month durability data from the trial. If those elements align — reproducible trial data, expanding coverage, and sustained device use — modelers should consider higher consumables growth rates and lower churn; if not, upside for DXCM may be limited to short-term sentiment moves.
Source: Original Article